COBAS AMPLICOR CT/NG Test for *Neisseria gonorrhoeae*

NGA
FOR IN VITRO DIAGNOSTIC USE

**Order Information**

<table>
<thead>
<tr>
<th>Kit Name</th>
<th>Type</th>
<th>Quantity</th>
<th>P/N</th>
<th>ART</th>
<th>US</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMPLICOR® CT/NG Specimen Preparation Kit</td>
<td>CT/NG PREP</td>
<td>100 Tests</td>
<td>20759414 122</td>
<td>07 5941 4</td>
<td>83315</td>
</tr>
<tr>
<td>AMPLICOR CT/NG Amplification Kit</td>
<td>CT/NG AMP</td>
<td>96 Tests</td>
<td>20759002 122</td>
<td>07 5990 2</td>
<td>83319</td>
</tr>
<tr>
<td>COBAS AMPLICOR Neisseria gonorrhoeae Detection Kit</td>
<td>NG DK</td>
<td>100 Tests</td>
<td>2075735 122</td>
<td>07 5753 5</td>
<td>83278</td>
</tr>
<tr>
<td>COBAS AMPLICOR Detection Reagents Kit</td>
<td>DK</td>
<td>100 Tests</td>
<td>2075740 122</td>
<td>07 5747 0</td>
<td>83276</td>
</tr>
<tr>
<td>COBAS AMPLICOR Conjugate Detection Reagent</td>
<td>CN4</td>
<td>200 Tests</td>
<td>20764213 123</td>
<td>07 6421 3</td>
<td>83305</td>
</tr>
<tr>
<td>COBAS AMPLICOR Wash Buffer Kit</td>
<td>WB</td>
<td>500 Tests</td>
<td>20759899 123</td>
<td>07 5989 9</td>
<td>83314</td>
</tr>
<tr>
<td>COBAS AMPLICOR Chlamydia trachomatis Detection Kit</td>
<td>CT DK</td>
<td>100 Tests</td>
<td>20757497 122</td>
<td>07 5749 7</td>
<td>83277</td>
</tr>
<tr>
<td>COBAS AMPLICOR Internal Control Detection Kit</td>
<td>IC DK</td>
<td>100 Tests</td>
<td>20757608 122</td>
<td>07 5760 8</td>
<td>83281</td>
</tr>
</tbody>
</table>

The following kit can be used to detect Chlamydia trachomatis in specimens amplified using the COBAS AMPLICOR CT/NG Amplification Kit. Detection of Chlamydia trachomatis is a user option.

The following kit can be used to detect the CT/NG Internal Control amplified using the COBAS AMPLICOR CT/NG Amplification Kit.
Intended Use

The COBAS AMPLICOR CT/NG Test for Neisseria gonorrhoeae is a qualitative *in vitro* test for the detection of *N. gonorrhoeae* DNA in urine from symptomatic or asymptomatic males, in endocervical swab specimens from symptomatic or asymptomatic females, and in urethral swab specimens from symptomatic males as evidence of infection with *N. gonorrhoeae*. *N. gonorrhoeae* DNA is detected by Polymerase Chain Reaction (PCR) amplification of target DNA and by hybridization capture of amplified target using the COBAS AMPLICOR™ Analyzer.

Summary and Explanation of the Test

*Neisseria gonorrhoeae* (gonococci) is the causative agent of gonorrhea. *N. gonorrhoeae* are gram-negative diplococci, cytochrome oxidase positive, non-motile and non-spore forming. *N. gonorrhoeae* is closely related genetically to *N. meningitidis* (meningococci), the causative agent of one type of bacterial meningitis, and slightly less related to *N. lactamica*, an occasional human pathogen. Both *N. gonorrhoeae* and *N. meningitidis* infect humans only. There are several additional species of *Neisseria* that may be considered normal flora in humans including *N. cinerea*, *N. elongata*, *N. flavescens*, *N. mucosa*, *N. sicca*, and *N. subflava*. Gonorrhea is the third most common cause of Sexually Transmitted Diseases (STD’s) with 62.2 million cases of gonorrhea being reported worldwide. In the United States alone, 351,852 cases of gonorrhea were reported in 2002. The total number of new cases of gonorrhea each year in the United States is estimated to be 700,000. In men, this disease generally results in anterior urethritis accompanied by purulent exudate. In women, the disease is most often found in the cervix, but the vagina and uterus may also be infected.

Presumptive diagnosis of gonorrhea is based on: (1) observation of gram-negative intracellular diplococci in gram-stained smears of urethral discharges from men and of endocervical secretions from women; (2) growth of *N. gonorrhoeae* from the urethra (men) or endocervix on selective culture media followed by demonstration of typical colonial morphology, positive oxidase activity, and typical gram-negative diploccal morphology; and/or (3) detection of *N. gonorrhoeae* with nonculture laboratory tests. A definitive diagnosis of gonorrhea requires (1) isolation of *Neisseria gonorrhoeae* from the sites of exposure by culture (48-72 hour cultures on selective medium), demonstration of typical colonial morphology, positive oxidase test, typical gram-negative morphology and (2) confirmation of *N. gonorrhoeae* culture isolates by specific identification methods (acid production from carbohydrates, rapid enzyme tests, serologic assays, tests for specific nucleic acid). Culture is required for determination of antimicrobial susceptibility.

Principles of the Procedure

The COBAS AMPLICOR CT/NG Test for *Neisseria gonorrhoeae* is based on four major processes: specimen preparation; PCR amplification of target DNA using NG specific complementary biotinylated primers; hybridization of the amplified DNA to oligonucleotide probes specific to the target(s); and detection of probe-bound amplified DNA by colorimetric determination.
The development of a PCR assay involves identifying the particular region of the target DNA to be amplified and synthesizing two short biotinylated oligonucleotide primers that are complementary to the regions flanking the target sequence. These biotinylated primers bind to the complementary flanking region, and the DNA polymerase extends the sequence in the 5' to 3' direction utilizing excess deoxynucleotide triphosphates (dNTPs) in the reaction mixture thereby creating a biotinylated, complementary DNA sequence termed an amplicon. An oligonucleotide probe, specific for the amplicon, is bound to a solid support (microparticles) and is used for hybridization (capture) of the amplicon. The assay detection system uses an avidin-horseradish peroxidase conjugate (HRP) that binds to biotinylated amplicon captured on the microparticles. A hydrogen peroxide ($H_2O_2$) substrate and tetramethylbenzidine (TMB) chromophore are used for color formation.

The COBAS AMPLICOR CT/NG Test is a multiplex assay that permits the simultaneous amplification of *N. gonorrhoeae* target DNA, *C. trachomatis* target DNA and CT/NG Internal Control DNA. The Master Mix reagent contains biotinylated primer pairs specific for *C. trachomatis* and *N. gonorrhoeae*. The CT/NG Internal Control contains identical primer binding sequences as the *C. trachomatis* target DNA and uses the *C. trachomatis* primers for amplification. The detection reactions are performed independently for *C. trachomatis*, *N. gonorrhoeae* and the CT/NG Internal Control.

**Specimen Preparation**

Urogenital epithelial cells, leukocytes and associated *N. gonorrhoeae* cells are collected on swabs or pelleted from urine. Specimens are treated with a detergent solution to lyse cells and release gonococcal DNA. A second detergent solution is then added to prepare the specimen for amplification.

**Target Selection**

*Neisseria gonorrhoeae* contain a highly-conserved DNA sequence (M·Ngo PII) that, based on sequence homology, apparently encodes a cytosine DNA methyltransferase, which inhibits the digestion of chromosomal DNA by HaeIII restriction endonuclease. The M·Ngo PII gene sequence (approximately 1044 base pairs) is present in the different strains of *N. gonorrhoeae*, and not found in most other, non-gonococcal Neisseria species. The COBAS AMPLICOR CT/NG Test for *Neisseria gonorrhoeae* uses the biotinylated primers SS01 and SS02 to define a sequence of approximately 201 nucleotides within the M·Ngo PII gene of *N. gonorrhoeae*.

**Target Amplification**

Processed specimens are added to the amplification mixture in amplification tubes (A-tubes) in which PCR amplification occurs. The COBAS AMPLICOR Analyzer thermal cycler heats the reaction mixture to denature the double-stranded DNA and expose the specific primer target sequences on the *Neisseria gonorrhoeae* M·Ngo PII gene. As the mixture cools, the biotinylated primers SS01 and SS02 anneal to the complementary sequence of *N. gonorrhoeae* DNA. The thermostable *Thermus aquaticus* DNA polymerase, (Taq pol), in the presence of excess deoxynucleoside triphosphates (dNTPs), including deoxyadenosine, deoxyguanosine, deoxyxystidine and deoxyuridine (in place of thymidine) triphosphates, extends the annealed primers along the target template to produce a 201-base pair double-stranded DNA molecule termed an amplicon. The COBAS AMPLICOR Analyzer automatically repeats this process for a designated number of cycles, each cycle effectively doubling the amount of amplicon DNA. The AMPLICOR CT/NG Master Mix also contains a second set of biotinylated
primers that co-amplify *Chlamydia trachomatis* (CT) target DNA in the specimen and the CT/NG Internal Control using an analogous process to that described for *Neisseria gonorrhoeae*.

**Internal Control Amplification**

In enzyme-based amplification processes such as PCR, efficiency can be reduced by inhibitors that may be present in the clinical specimen. The CT/NG Internal Control permits the optional identification of processed specimens containing substances that may interfere with PCR amplification. The CT/NG Internal Control is a non-infectious recombinant plasmid DNA with primer binding regions identical to those of the *C. trachomatis* target sequence, a randomized internal sequence of similar length and base composition as the NG and CT target sequences, and a unique probe binding region distinct from the target amplicon. These features were selected to ensure equivalent amplification of the CT/NG Internal Control and CT/NG target DNA. The CT/NG Internal Control Reagent is included in the AMPLICOR CT/NG Amplification Kit and is introduced into each amplification reaction to be co-amplified with target DNA from the clinical specimen. The optional COBAS AMPLICOR Internal Control Detection Kit contains an IC-specific oligonucleotide capture probe that can be used to identify a positive IC signal in the reaction mixture. The CT/NG Internal Control is designed to ensure that specimens do not contain inhibitors that would interfere with the amplification and detection of 20 or more copies of *N. gonorrhoeae* target nucleic acid as determined by Poisson analysis. The CT/NG Internal Control is added to the Master Mix and is co-amplified with target DNA from the clinical specimen.

**Selective Amplification**

Selective amplification of target DNA from the clinical specimen in the COBAS AMPLICOR CT/NG Test is achieved by the use of AmpErase (uracil-N-glycosylase) enzyme (microbial) and deoxyuridine triphosphate (dUTP). AmpErase enzyme recognizes and catalyzes the destruction of DNA containing deoxyuridine but not DNA strands containing deoxythymidine. Deoxyuridine is not present in naturally occurring DNA, but is always present in amplicon due to the use of deoxyuridine triphosphate in place of thymidine triphosphate as one of the dNTPs in the Master Mix reagent; therefore, only amplicon contain deoxyuridine. Deoxyuridine renders contaminating amplicon susceptible to destruction by AmpErase enzyme prior to amplification of target DNA. AmpErase enzyme, which is included in the Master Mix reagent, catalyzes the cleavage of deoxyuridine-containing DNA at the deoxyuridine residues by opening the deoxyribose chain at the C1-position. When heated in the first thermal cycling step at the alkaline pH of the Master Mix, the amplicon DNA chain breaks at the position of the deoxyuridine, thereby rendering the DNA non-amplifiable. AmpErase enzyme is inactive at temperatures above 55°C, i.e., throughout the thermal cycling steps, and therefore does not destroy target amplicon. Following amplification, any residual enzyme is denatured by the addition of the Denaturation Solution, thereby preventing the degradation of any target amplicon. AmpErase enzyme in the COBAS AMPLICOR CT/NG Test for *Neisseria gonorrhoeae* has been demonstrated to inactivate at least 10^3 copies of deoxyuridine containing amplicon per PCR.
**Hybridization Reaction**

Following PCR amplification, the COBAS AMPLICOR Analyzer automatically adds Denaturation Solution to the reaction mixture in each A-tube to chemically denature the NG amplicon and the CT/NG Internal Control amplicon to form single-stranded DNA. Aliquots of denatured amplicon from each A-tube are then transferred by the Analyzer to individual detection cups (D-cups). A suspension of magnetic particles coated with an oligonucleotide probe specific for *N. gonorrhoeae* (or Internal Control, at the user’s option) is added to individual D-cups. The biotin labeled NG and CT/NG Internal Control amplicon are hybridized to the target-specific oligonucleotide probe-bound magnetic particles. The hybridization of amplicon to target-specific probe enhances the overall specificity of the test.

**Detection Reaction**

Following the hybridization reaction, the COBAS AMPLICOR Analyzer washes the magnetic particles in each D-cup to remove unbound material and then adds Avidin-Horseradish Peroxidase Conjugate. The Avidin-Horseradish Peroxidase Conjugate binds to biotin-labeled amplicon hybridized to the target specific oligonucleotide probe bound to the magnetic particles. The COBAS AMPLICOR Analyzer removes unbound conjugate by washing the magnetic particles and then adds a substrate solution containing hydrogen peroxide and 3,3',5,5' tetramethylbenzidine (TMB) to each D-cup. In the presence of hydrogen peroxide, the particle-bound horseradish peroxidase catalyzes the oxidation of TMB to form a colored complex, the absorbance of which is measured by the COBAS AMPLICOR Analyzer at a wavelength of 660 nm.

**Reagents**

**AMPLICOR CT/NG Specimen Preparation Kit**

**CT/NG PREP** 100 Tests

<table>
<thead>
<tr>
<th>Test Code</th>
<th>Description</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>ART: 07 5941 4</td>
<td>CT/NG URINE WASH (CT/NG Urine Wash Buffer)</td>
<td>1 x 50 mL</td>
</tr>
<tr>
<td>US: 83315</td>
<td>Tris-HCl buffer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>300 mM NaCl</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&lt; 0.1% Detergent</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.09% Sodium azide</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CT/NG LYS (CT/NG Lysis Reagent)</td>
<td>1 x 25 mL</td>
</tr>
<tr>
<td></td>
<td>Tris-HCl buffer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&lt; 1% Solubilizer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.09% Sodium azide</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CT/NG DIL (CT/NG Specimen Diluent)</td>
<td>2 x 50 mL</td>
</tr>
<tr>
<td></td>
<td>Tris-HCl buffer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6 mM Magnesium chloride</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&lt; 25% Detergent</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.05% Sodium azide</td>
<td></td>
</tr>
</tbody>
</table>
CT/NG MMX
(CT/NG Master Mix)
Tris-HCl buffer
EDTA
100 mM KCl
Glycerol
< 0.01% AmpliTaq (Taq DNA Polymerase, microbial)
< 0.005% dATP, dCTP, and dGTP
< 0.016% dUTP
< 0.01% AmpErase (uracil-N-glycosylase) enzyme (microbial)
< 0.0004% CP24 and CP27 primers, biotinylated
0.05% Sodium azide

CT/NG IC
(CT/NG Internal Control)
Tris-HCl buffer
8 Copies/µL non-infectious plasmid DNA (microbial) containing
CT primer binding sequences and a unique probe binding region
(equivalent to approx. 21 IC copies/test)
< 0.005% Poly rA RNA (synthetic)
EDTA
Amaranth dye
0.05% Sodium azide

NG (+) C
[N. gonorrhoeae (+) Control]
Tris-HCl buffer
8.6 Copies/µL of non-infectious plasmid DNA (synthetic)
containing N. gonorrhoeae sequences equivalent to
approximately 20 copies/test
< 0.005% Non-specific carrier DNA (mammalian)
< 0.5% Detergent
EDTA
0.05% Sodium azide

CT (+) C
[N. gonorrhoeae (-) Control]
Tris-HCl buffer
8.6 Copies/µL of non-infectious plasmid DNA (synthetic)
containing C. trachomatis sequences equivalent to
approximately 20 copies/test
< 0.005% Non-specific carrier DNA (mammalian)
< 0.5% Detergent
EDTA
0.05% Sodium azide
Neisseria gonorrhoeae

COBAS AMPLICOR Neisseria gonorrhoeae Detection Kit

NG PS1 (NG Probe Suspension 1)
MES buffer
< 0.3% Suspension of Dynabeads® (paramagnetic particles) coated with N. gonorrhoeae-specific oligonucleotide capture probe
0.09% Sodium azide

NG4 (NG Probe Suspension 2)
Sodium phosphate buffer
37% Sodium thiocyanate
< 0.2% Detergent

IC PS1 (IC Probe Suspension 1)
MES buffer
< 0.35% Suspension of Dynabeads (paramagnetic particles) coated with Internal Control-specific oligonucleotide capture probe
0.09% Sodium azide

IC4 (IC Probe Suspension 2)
Sodium phosphate buffer
25% Sodium thiocyanate
< 0.2% Detergent

Harmful
COBAS AMPLICOR Detection Reagents Kit

DN4
(Denaturation Solution)
1.6% Sodium hydroxide
EDTA
Thymol blue

Xi 1.6% (w/w) Sodium hydroxide

Irritant

CN4
(Avidin-Horseradish Peroxidase Conjugate)
Tris-HCl buffer
< 0.001% Avidin-horseradish peroxidase conjugate
Bovine serum albumin (mammalian)
Emulsit 25 (Dai-ichi Kogyo Seiyaku Co., Ltd.)
0.1% Phenol
1% ProClin® 150

SB3
(Substrate A)
Citrate solution
0.01% Hydrogen peroxide
0.1% ProClin 150

SB
(Substrate B)
0.1% 3,3',5,5'-Tetramethylbenzidine (TMB)
40% Dimethylformamide (DMF)

T 40% (w/w) Dimethylformamide (DMF)

Toxic

R: 61-20/21-36 May cause harm to the unborn child.
Harmful by inhalation and in contact with skin. Irritating to eyes.

S: 53-45 Avoid exposure - obtain special instructions before use. In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
**COBAS AMPLICOR**

**Conjugate Detection Reagent**

CN4  200 Tests  P/N: 20764213 123  
ART: 07 6421 3  
US: 83305

**CN4**

(Avidin-Horseradish Peroxidase Conjugate)  
Tris-HCl buffer  
< 0.001% Avidin-horseradish peroxidase conjugate  
Bovine serum albumin (mammalian)  
Emulsit 25 (Dai-ichi Kogyo Seiyaku Co., Ltd.)  
0.1% Phenol  
1% ProClin 150

**COBAS AMPLICOR**

**Wash Buffer**

WB  500 Tests  P/N: 20759899 123  
ART: 07 5989 9  
US: 83314

**WB**

(10X-Wash Concentrate)  
< 2% Phosphate buffer  
< 9% Sodium chloride  
EDTA  
< 2% Detergent  
0.5% ProClin 300

---

**Warnings and Precautions**

*For in vitro diagnostic use.*

The use of the term copy in this method manual refers to 1 copy of *N. gonorrhoeae* target nucleic acid. One (1) copy is equivalent to the smallest amount of *N. gonorrhoeae* target nucleic acid that would generate a positive PCR test result.

This test is for use only with endocervical specimens, male urethral specimens from symptomatic patients, and male urine specimens. This test is not intended for use with male urethral specimens from asymptomatic patients, female urine specimens, and throat, rectal, or other types of specimens.

Specimens are stable for the timepoints indicated in the "Specimen Collection, Transport and Storage" section of this product insert. However, testing of all specimens at the earliest interval following collection will help ensure the most accurate test results. Multiple variable effects of storage times and variations associated with specimen shipment have not been assessed.

Do not pipet by mouth.

Do not eat, drink or smoke in laboratory work areas. Wear protective disposable gloves, laboratory coats and eye protection when handling specimens and kit reagents. Wash hands thoroughly after handling specimens and kit reagents.

Avoid microbial contamination of reagents when removing aliquots from reagent bottles. The use of sterile disposable pipets and pipet tips is recommended.
Do not pool reagents from different lots or from different bottles of the same lot.

Dispose of unused reagents and waste in accordance with country, federal, state, and local regulations.

Do not use a kit after its expiration date.

Material Safety Data Sheets (MSDS) are available on request from your local Roche office.

Workflow in the laboratory must proceed in a uni-directional manner, beginning in the Pre-Amplification Area and moving to the Post-Amplification (Amplification/Detection) Area. Pre-amplification activities must begin with reagent preparation and proceed to specimen preparation. Supplies and equipment must be dedicated to each pre-amplification activity and not used for other activities or moved between areas. Gloves must be worn in each area and must be changed before leaving that area. Equipment and supplies used for reagent preparation must not be used for specimen preparation activities or for pipetting or processing amplified DNA or other sources of target DNA. Post-amplification supplies and equipment must remain in the Post-Amplification Area at all times.

Specimens should be handled as if infectious using safe laboratory procedures such as those outlined in *Biosafety in Microbiological and Biomedical Laboratories* and in the NCCLS Document M29-A. Thoroughly clean and disinfect all work surfaces with a freshly prepared solution of 0.5% sodium hypochlorite in deionized or distilled water.

**Note**

*Commercial liquid household bleach typically contains sodium hypochlorite at a concentration of 5.25%. A 1:10 dilution of household bleach will produce a 0.5% sodium hypochlorite solution.*

The COBAS AMPLICOR CT/NG Test for *N. gonorrhoeae* may react with *N. subflava* and *N. cinerea*. These organisms may be common components of normal throat flora. Avoid contaminating specimen processing reagents, amplification reagents and patient specimens with respiratory aerosols.

For specimens transported in Chlamydia culture transport media, swabs should be left in the culture transport tube to provide visual evidence of specimen inoculation. The COBAS AMPLICOR CT/NG Test for *N. gonorrhoeae* was evaluated using specimens transported with the swab in the Chlamydia culture transport medium (CTM) tube. CTM specimens transported without swabs have not been evaluated and are not recommended for use with this test.

Storage of urine specimens at room temperature for more than 24 hours may result in specimen degradation. Urine specimens stored for longer than 24 hours at room temperature should not be used for testing.

**CT/NG URINE WASH, CT/NG LYS, CT/NG DIL, CT/NG MMX, CT/NG IC, NG (+) C, CT (+) C, NG PS1 and IC PS1** contain sodium azide. Sodium azide may react with lead and copper plumbing to form highly explosive metal azides. While disposing of sodium azide containing solutions down laboratory sinks, flush the drains with a large volume of water to prevent azide buildup.
Neisseria gonorrhoeae

Wear eye protection, laboratory coats and disposable gloves when handling DN4, CN4, SB3, SB, and Working Substrate (mixed SB3 and SB reagent). Avoid contact of these materials with the skin, eyes or mucous membranes. If contact does occur, immediately wash with large amounts of water. Burns can occur if left untreated. If spills of these reagents occur, dilute with water before wiping dry.

Avoid contact between the skin or mucous membranes and SB or the Working Substrate. If skin contact occurs, wash immediately with large amounts of water.

SB and Working Substrate contain dimethylformamide which has been reported to be toxic in high oral doses and may be harmful to the unborn child. Skin contact, inhalation of fumes and ingestion must be avoided. If skin contact occurs, wash thoroughly with soap and water and seek medical advice immediately.

Screw-cap tubes must be used for specimen and control preparation to prevent splashing and potential cross-contamination of specimens. Do not use snap cap tubes.

Storage and Handling Requirements

Do not freeze reagents.

Store CT/NG LYS at 2-25°C. Store CT/NG URINE WASH and CT/NG DIL at 2-8°C. If a precipitate forms in either of these reagents during storage, warm to ambient temperature and mix thoroughly prior to use. These reagents are stable until the expiration date indicated.

Store CT/NG MMX and CT/NG IC at 2-8°C. These reagents are stable until the expiration date indicated. Working Master Mix (prepared by the addition of CT/NG IC to CT/NG MMX) must be stored at 2-8°C and is stable for 4 weeks.

Store NG (+) C and CT (+) C at 2-8°C. These reagents are stable until the expiration date indicated.

Store NG PS1 and NG4 at 2-8°C. These reagents are stable until the expiration date indicated. Once NG PS1 and NG4 are mixed, the Working Reagent is stable for 30 days at 2-8°C. This Working Reagent can be used for a maximum of 6 instrument cycles (12 hours per cycle) and must be stored at 2-8°C between instrument cycles.

Store IC PS1 at 2-8°C. Store IC4 at 2-8°C. These reagents are stable until the expiration date indicated. Once IC PS1 and IC4 are mixed, the Working Reagent is stable for 21 days at 2-8°C. This Working Reagent can be used for a maximum of 6 instrument cycles (12 hours per cycle) and must be stored at 2-8°C between instrument cycles.

Store DN4 at 2-25°C. DN4 is stable until the expiration date indicated. Once opened, DN4 is stable for 30 days at 2-8°C or until the expiration date, whichever comes first. DN4 can be used for a maximum of 6 instrument cycles (12 hours per cycle) and must be stored at 2-8°C between instrument cycles.
Store CN4 at 2-8°C. CN4 is stable until the expiration date indicated. Once opened, CN4 reagent is stable for 30 days at 2-8°C or until the expiration date, whichever comes first. CN4 can be used for a maximum of 6 instrument cycles (12 hours per cycle) and must be stored at 2-8°C between instrument cycles.

Store SB3 and SB at 2-8°C. Unopened, these reagents are stable until the expiration dates indicated. Working Substrate must be prepared each day by mixing SB3 with SB. The Working Substrate is stable on the COBAS AMPLICOR Analyzer for 16 hours. Do not expose SB3, SB, or Working Substrate to metals, oxidizing agents or direct light.

Store WB at 2-30°C. WB is stable until the expiration date indicated. Examine the WB, and if necessary, warm at 30-37°C to redissolve any precipitate. Working Wash Buffer (1X), prepared by diluting WB 1:10 with distilled or deionized water must be stored at 2-25°C in the COBAS AMPLICOR Wash Buffer Reservoir and is stable for 2 weeks from the date of preparation.

Store partially used detection reagents at 2-8°C between instrument runs. Check expiration date of opened or Working Reagents prior to loading on the COBAS AMPLICOR Analyzer.

### Materials Provided

**AMPLICOR CT/NG Specimen Preparation Kit**

- **CT/NG PREP**
  - P/N: 20759414 122
  - ART: 07 5941 4
  - US: 83315

**CT/NG URINE WASH**

- (CT/NG Urine Wash Buffer)

**CT/NG LYS**

- (CT/NG Lysis Reagent)

**CT/NG DIL**

- (CT/NG Specimen Diluent)

**AMPLICOR CT/NG Amplification Kit**

- **CT/NG AMP**
  - P/N: 20759902 122
  - ART: 07 5990 2
  - US: 83319

- **CT/NG MMX**
  - (CT/NG Master Mix)

- **CT/NG IC**
  - (CT/NG Internal Control)

- **NG (+) C**
  - [N. gonorrhoeae (+) Control]

- **CT (+) C**
  - [C. trachomatis (+) Control]

**COBAS AMPLICOR Neisseria gonorrhoeae Detection Kit**

- **NG PS1**
  - (NG Probe Suspension 1)

- **NG4**
  - (NG Probe Suspension 2)

---

12/43 COBAS AMPLICOR CT/NG Test for Neisseria gonorrhoeae 10/2004, Revision 5.0
Neisseria gonorrhoeae

COBAS AMPLICOR Internal Control Detection Kit
IC DK
P/N: 20757608 122
ART: 07 5760 8
US: 83281

IC PS1
(IC Probe Suspension 1)
IC4
(IC Probe Suspension 2)

COBAS AMPLICOR Detection Reagents Kit
DK
P/N: 20757470 122
ART: 07 5747 0
US: 83276

DN4
(Denaturation Solution)
CN4
(Avidin-Horseradish Peroxidase Conjugate)
SB3
(Substrate A)
SB
(Substrate B)

COBAS AMPLICOR Conjugate Detection Reagent
CN4
P/N: 20764213 123
ART: 07 6421 3
US: 83305

CN4
(Avidin-Horseradish Peroxidase Conjugate)

COBAS AMPLICOR Wash Buffer
WB
P/N: 20757497 122
ART: 07 5989 9
US: 83314

(W10X-Wash Concentrate)

Materials Required But Not Provided

Specimen Collection

- Endocervical and urethral specimen collection swabs - use only dacron, rayon, or calcium alginate tipped collection swabs with plastic or non-aluminum wire shafts
- Chlamydia Culture Transport Media (CTM) - use only 2SP CTM, Bartels ChlamTrans™ Chlamydial Transport Medium (Bartels, Inc.), SPG CTM, or M4 CTM (MicroTest, Inc.)
- Polypropylene, preservative-free urine collection cups

Pre-Amplification - Reagent Preparation Area

- COBAS AMPLICOR A-ring fitted with 12 A-tubes (ART: 10 4563 6)
- COBAS AMPLICOR A-ring holder
- Eppendorf® Repeater™ pipet with 1.25 mL Combitip® Reservoir (sterile, individually wrapped)
– Pipettors (capacity 100 µL)* with aerosol barrier or positive displacement tips
– Vortex mixer
– Disposable gloves, powderless
– Plastic resealable bag

Pre-Amplification - Specimen and Control Preparation Area

– 2.0 mL polypropylene screw-cap tubes, sterile, non-siliconized, conical (Sarstedt 72.693.105 or equivalent)**
– Tube racks (Sarstedt 93.1428 or equivalent)
– Pipettors (capacity 50 µL, 100 µL, 200 µL, 250 µL, 500 µL and 1000 µL)* with aerosol barrier or positive displacement tips
– Microcentrifuge (max. RCF 16,000 x g, min. RCF 12,500 x g); Eppendorf 5415C, HERMLE Z230M, or equivalent
– Extended aerosol barrier tips (Matrix 7055 or equivalent) for use with specimens transported in M4 Culture Transport Medium or Bartels ChlamTrans Chlamydial Transport Medium
– 37°C ± 2°C heating block
– Vortex mixer
– Absorbent paper
– Disposable gloves, powderless

Post-Amplification - Amplification/Detection Area

– COBAS AMPLICOR Analyzer and printer
– Operator's Manual for the COBAS AMPLICOR Analyzer
– COBAS AMPLICOR CT/NG Test for Neisseria gonorrhoeae Method Manual
– Racks of D-cups (ART: 10 4564 4)
– Distilled or deionized water
– 5 mL serological pipets
– Graduated cylinder (minimum 1 Liter)
– Vortex mixer
– Disposable gloves, powderless

* Pipettors should be accurate within 3% of stated volume. Aerosol barrier or positive displacement tips must be used where specified to prevent specimen and amplicon cross-contamination.

**Screw-cap tubes must be used for specimen and control preparation to prevent splashing and potential cross-contamination of specimens and controls. Do not use snap cap tubes.
Specimen Collection, Transport and Storage

**Note** Handle all specimens as if they are capable of transmitting infectious agents.

The only acceptable specimens are:

1. Male urine specimens transported in clean polypropylene containers without preservatives. **Do not use urine specimens collected in containers containing preservatives.**

2. Endocervical specimens from asymptomatic or symptomatic patients and male urethral swab specimens from symptomatic patients. Specimens must be collected and transported in 2SP Culture Transport Medium, Bartels ChlamTrans Chlamydial Transport Medium (Bartels, Inc.), or M4 Culture Transport Medium (MicroTest, Inc.). Media lots should be qualified for use in each laboratory (see Quality Control section for details).

For reliable test results, follow instructions below for proper specimen collection. This test is not intended for use with throat, rectal, or other types of specimens other than those indicated.

In order to ensure the delivery of high quality specimens to the laboratory for testing, urine and urogenital swab specimens should be transported to the laboratory in as short a time as practical. Do not allow specimens to be transported without controlled temperature conditions.

**Specimen Collection**

**Male Urine Specimens**

**Note** Patient must not have urinated during the previous 2 hours.

1. Collect 10 to 50 mL of first catch urine (the first part of the stream) into a clean polypropylene container without preservatives.

2. Seal the specimen container and label appropriately. The specimen may be transported to the test site at room temperature (18-30°C).

**Swab Specimens Collected in Culture Transport Media (CTM)**

1. Endocervical and male urethral swab specimens can be collected and transported in 1 to 3 mL 2SP Culture Transport Medium, Bartels ChlamTrans Chlamydial Transport Medium (Bartels, Inc.), SPG Culture Transport Medium, or M4 Culture Transport Medium (MicroTest, Inc.). Use recommended methods for obtaining swab specimens after removing cervical mucus.

2. Use only dacron, rayon, or calcium alginate tipped collection swabs with plastic or non-aluminum wire shafts. Do not use collection swabs with wooden or aluminum shafts.

3. Leave swabs in the transport media. Seal the specimen container and label appropriately. Follow the laboratory’s collection and transport procedure. Refrigerate swab specimens if transport to the laboratory is delayed for more than one hour from the time of collection.
Specimen Transport

Male Urine Specimens

1. Urine specimens may be transported to the test site at 18 - 30°C. Urine specimens are stable for 24 hours at room temperature. Urine specimens that will not be processed within 24 hours of collection must be stored at 2-8°C and must be processed within 7 days of collection. Urine specimens that cannot be processed within 7 days of collection can be stored at -20°C or lower and tested within 30 days of the date of collection.

2. Urine specimens that require shipment to off-site test centers must be shipped via overnight delivery with guaranteed arrival within 24 hours; shipment can be at room temperature (18-30° C). If urine specimens are shipped at room temperature, they should be stored at 2-8°C until time of shipment to ensure that the period of room temperature storage does not exceed 24 hours. Specimens must be shipped in compliance with all applicable local, state and country regulations for the transport of etiologic agents.

Swab Specimens Collected in Culture Transport Media (CTM)

1. Refrigerate swab specimens if transport to the laboratory or if specimen processing is delayed for more than one hour from the time of collection. Swab specimens that require shipment to off-site laboratories should be shipped as soon as possible after collection according to the laboratory’s procedures for the transport of Chlamydial culture specimens.

2. Store swab specimens that are not tested upon receipt at the testing laboratory at 2-8°C and process within 7 days. Swab specimens that cannot be processed within 7 days of collection must be stored at -20°C or colder and tested within 30 days of the date of collection.

Specimen Storage

Note

Routine freezing or prolonged storage of specimens may affect performance.

Male Urine Specimens

1. Urine specimens that will not be processed within 24 hours of collection must be stored at 2-8°C and must be processed within 7 days of collection. Urine specimens that cannot be processed within 7 days of collection can be stored at -20°C or lower for up to 30 days.

Swab Specimens Collected in Culture Transport Media (CTM)

1. Store swab specimens that are not tested upon receipt at the testing laboratory at 2-8°C and process within 7 days. Swab specimens that cannot be processed within 7 days of collection must be stored at -20°C or colder and tested within 30 days of collection.
Instructions For Use

Note For detailed operating instructions, refer to the Operator's Manual for the COBAS AMPLICOR Analyzer.

Note All reagents must be at ambient temperature before use. Use pipettors with aerosol barrier or positive displacement tips where specified. Use extreme care to ensure selective amplification.

Note Urine and swab specimens must be at ambient temperature before use. Use pipettors with aerosol barrier or positive displacement tips where specified. Use extreme care to ensure selective amplification.

Note Screw-cap tubes must be used for specimen and control preparation to prevent splashing and potential cross-contamination of specimens. Do not use snap cap tubes.

Run Size Each kit contains reagents sufficient for eight 12-specimen runs, which may be performed separately or simultaneously. At least one replicate of the COBAS AMPLICOR N. gonorrhoeae (+) Control and one replicate of the COBAS AMPLICOR C. trachomatis (+) Control must be included in each test run (see "Quality Control" section).

Note The C. trachomatis (+) Control serves as the N. gonorrhoeae (-) Control for the COBAS AMPLICOR CT/NG Test for Neisseria gonorrhoeae.

The Specimen Preparation Reagents are packaged to perform 100-tests. The N. gonorrhoeae (+) Controls and C. trachomatis (+) Controls are supplied in single bottles containing enough material to prepare 8 sets of processed controls. The CT/NG Master Mix and the CT/NG Internal Control are provided in three bottles each containing enough material to perform 32 specimen runs. For the most efficient use of reagents, specimens and controls should be processed in batches that are multiples of 12.

Workflow The COBAS AMPLICOR CT/NG Test for Neisseria gonorrhoeae can be completed in one day or over two days. If the testing is to be completed in a single workday, follow the instructions in Reagent Preparation, Specimen Preparation, Control Preparation, Amplification and Detection in order. Testing can be completed over 2 days by performing Specimen Preparation on Day 1, followed by Reagent Preparation, Control Preparation, Amplification and Detection on Day 2. Alternatively, perform Reagent Preparation, Specimen Preparation and Control Preparation; and add prepared specimens and controls to Master Mix on Day 1, followed by Amplification and Detection on Day 2.

Reagent Preparation Performed in: Pre-Amplification – Reagent Preparation Area

1. Determine the appropriate number of A-rings needed for patient specimen and control testing. Place the A-ring(s) in the A-ring holder(s).

Note Even if CT/NG Internal Control detection will not be performed, CT/NG IC must be added to the Master Mix.
2. Prepare Working Master Mix by adding 100 µL of CT/NG IC to one vial of CT/NG MMX. Mix well by inverting 10-15 times. Working Master Mix must be stored at 2-8°C and used within 4 weeks of preparation.

3. Add 50 µL of Working Master Mix into each A-tube using a repeater pipet or a pipettor with an aerosol barrier tip or a positive displacement tip. **Do not close the covers of the A-tube(s) at this time.**

4. Place the A-ring(s) containing Working Master Mix in a resealable plastic bag and seal the plastic bag securely. Move the A-ring(s) to the Pre-Amplification Specimen Preparation Area. Store the A-ring(s) containing Working Master Mix at 2-8°C in the Pre-Amplification-Specimen Preparation Area until specimen and control preparation is complete. Working Master Mix is stable for 48 hours at 2-8°C in A-tubes sealed in the plastic bag.

Specimen Preparation

**Performed in: Pre-Amplification – Specimen Preparation**

**Urine Specimens (Male)**

1. Label one 2.0 mL screw-cap tube for each patient specimen. **Do not use snap cap tubes.**

2. Add 500 µL of CT/NG URINE WASH to each of the labeled tubes.

3. Vortex urine thoroughly (3-10 seconds). If using frozen specimens, thaw the specimens at room temperature before vortexing (**volumes greater than 2 mL must be thawed overnight at 2-8°C**); continue processing even if a precipitate is present. Carefully remove caps from urine specimen containers. Take care to avoid contaminating gloves with urine in the cap. If contamination occurs, replace with a clean pair before proceeding to the next specimen.

4. Add 500 µL of each well-mixed patient urine to the appropriate tube containing CT/NG URINE WASH. Use a new aerosol barrier tip for each specimen. Recap the tubes and mix well by vortexing.

5. Incubate at 37°C for 15 minutes.

6. Centrifuge at ≥ 12,500 x g for 5 minutes.

7. Pour off supernatant and blot each tube on a separate sheet of absorbent paper.

8. Using a new aerosol barrier pipet tip for each specimen, add 250 µL of CT/NG LYS to each tube. Recap tubes and mix well by vortexing.

9. Incubate tubes for 15 minutes at room temperature.

10 Using a new aerosol barrier pipet tip for each specimen, add 250 µL of CT/NG DIL to each tube. Recap tubes and mix well by vortexing.

11. Centrifuge tubes for 10 minutes at ≥ 12,500 x g.

12. Processed specimens may be kept at room temperature for up to 2 hours before transferring aliquots to the A-tubes containing Working Master Mix. Store processed specimens at 2-8°C if aliquots will not be added to the A-tubes within 2 hours. Processed specimens stored at 2-8°C must be tested within 7 days.
13. If processed specimens were stored at 2-8°C, they must be warmed to room temperature and mixed well by vortexing prior to amplification. After vortexing, centrifuge processed specimens for 10 minutes at ≥ 12,500 x g.

14. Using a pipettor with an aerosol barrier tip, transfer 50 µL of the supernatant to the appropriate A-tube. Use a new aerosol barrier tip for each specimen. Be careful not to disturb the pellet (pellet may not be clearly visible). Record the positions of the patient specimens on the A-ring map. Cap the A-tubes.

15. Store the remainder of each processed specimen at 2-8°C in the event retesting is required. Any retesting must be performed within 7 days of specimen processing.

**Swab Specimens (Male and Female)**

**Note**

The COBAS AMPLICOR CT/NG Test for Neisseria gonorrhoeae has been evaluated for use with 2SP Culture Transport Medium, SPG Culture Transport Medium, Bartels ChlamTrans Chlamydial Transport Medium (Bartels, Inc.) and M4 Culture Transport Medium (MicroTest, Inc.) The use of alternative transport media should be evaluated by the laboratory.

1. Check that the culture transport media tube contains a swab. Performance specifications have not been developed for this test for specimens that do not contain swabs.

2. Label one 2.0 mL screw-cap tube for each patient specimen. Do not use snap cap tubes.

3. Add 100 µL of CT/NG LYS to the appropriate labeled 2.0 mL polypropylene tubes.

4. Mix specimens by vortexing. If specimens were stored frozen, thaw at room temperature before vortexing. Carefully remove caps from specimen tubes. Take care to avoid contamination of gloves. If contamination should occur, replace gloves with a clean pair before proceeding to the next specimen.

5. Using a pipettor with an aerosol barrier tip, add 100 µL of well-mixed specimen to the appropriate tube containing CT/NG LYS. Use a new aerosol barrier tip for each specimen. Recap the tube and mix well by vortexing.

6. Incubate at room temperature for 10 minutes.

7. Using a new aerosol barrier pipet tip for each sample, add 200 µL of CT/NG DIL to each tube. Recap the tube and mix well by vortexing.

8. Incubate at room temperature for 10 minutes.

9. Processed specimens may be kept at room temperature for up to 2 hours before transferring aliquots to A-tubes containing Working Master Mix. Store processed specimens at 2-8°C if aliquots will not be added to the A-tubes within 2 hours. Processed specimens stored at 2-8°C must be tested within 7 days.
10. If processed specimens were stored at 2-8°C, they must be warmed to room temperature and mixed well by vortexing prior to amplification.

11. Using a pipettor with an aerosol barrier tip, transfer 50 µL of each processed specimen to the appropriate A-tube. Use a new aerosol barrier tip for each specimen. Record the positions of the patient specimens on the A-ring map. Cap the A-tubes.

12. Store the remainder of each processed specimen at 2-8°C in the event retesting is required. Any retesting must be performed within 7 days of specimen processing.

**Control Preparation**

**Performed in:** Pre-Amplification – Specimen and Control Area

**Note**

*Working Controls must be prepared fresh each day the test is performed. Working Controls can be used to prepare multiple Processed Controls during the day, but must be discarded at the end of the day.*

**Note**

*The NG (+) C serves as the positive control for the NG Test and the negative control for the CT Test. The CT (+) C serves as the negative control for the NG Test and the positive control for the CT Test. Therefore, when running both the NG and CT Tests on a sample, it is only necessary to prepare one set of the appropriate controls. If testing both swab and urine sample types, it is necessary to prepare one set of controls for each sample type.*

**A. Working Controls:**

Prepare the following NG (+) and NG (-) Working Controls.

1. Using a sterile pipet tip, add 1 mL of CT/NG DIL to each of two 2.0 mL screw-cap polypropylene tubes. Label one tube "NG (+) Working Control" and label the other tube "NG (-) Working Control".

2. Vortex the NG (+) C and CT (+) C for 5 seconds at maximum speed. Carefully remove the caps from the tubes. Take care to avoid contamination of gloves. If contamination should occur, replace gloves with a clean pair before proceeding.

3. Using a pipettor with a new aerosol barrier tip, add 100 µL of the NG (+) C to the tube labeled "NG (+) Working Control".

4. Using a pipettor with a new aerosol barrier tip, add 100 µL of the CT (+) C to the tube labeled "NG (-) Working Control".

5. Recap the tubes and mix well by vortexing. Store at room temperature and discard at the end of the workday.

**B. Urine Specimens:**

Prepare the following NG (+) and NG (-) Processed Controls.

1. Using a sterile pipet tip, add 250 µL CT/NG LYS into each of two 2.0 mL screw-cap polypropylene tubes. Label one tube "NG (+) Processed Control" and label the other tube "NG (-) Processed Control".

2. Using a pipettor with a new aerosol barrier tip, add 250 µL of the NG (+) Working Control to the tube labeled "NG (+) Processed Control".

3. Using a pipettor with a new aerosol barrier tip, add 250 µL of the NG (-) Working Control to the tube labeled "NG (-) Processed Control".
C. Swab Specimens: Prepare the following NG (+) and NG (-) Processed Controls.

1. Using a sterile pipet tip, add 100 µL of CT/NG LYS to each of two 2.0 mL screw-cap polypropylene tubes. Label one tube "NG (+) Processed Control" and label the other tube "NG (-) Processed Control".

2. Using a sterile pipet tip, add 100 µL of Culture Transport Medium to each of the tubes containing CT/NG LYS.

3. Re-cap the tubes and mix well by vortexing.

4. Using a pipettor with a new aerosol barrier tip, add 200 µL of the NG (+) Working Control to the tube labeled "NG (+) Processed Control".

5. Using a pipettor with a new aerosol barrier tip, add 200 µL of the NG (-) Working Control to the tube labeled "NG (-) Processed Control".

6. Re-cap the tubes and mix well by vortexing. Incubate for 10 minutes at room temperature. Store at room temperature and discard at the end of the workday.

7. Using a pipettor with an aerosol barrier tip, transfer 50 µL of each Processed Control to the appropriate A-tube. Cap the A-tubes and record the positions of the processed specimens and controls on the A-ring map.

8. Move the prepared samples (patient specimens and controls) in the A-rings to the Post-Amplification Area. These PCR-ready samples may be stored at 2-8°C for 16 hours.

Amplification and Detection

Performed in: Post-Amplification Area - Amplification/Detection

Perform Daily Instrument Maintenance as outlined in the Operator's Manual for the COBAS AMPLICOR Analyzer including:

- Wipe initialization post with a lint-free moist cloth and dry
- Wipe D-cup handler tip with a lint-free moist cloth and dry
- Check Wash Buffer Reservoir and fill if necessary
Prepare Working Wash Buffer (1X) as follows. Examine WB and if necessary, warm at 30-37°C to redissolve any precipitate. Add 1 volume of WB to 9 volumes of distilled or deionized water. Mix well. Keep a minimum of 3-4 liters of Wash Buffer (1X) in the Wash Buffer Reservoir of the system at all times.

- Empty waste container
- Prime the system
- During the priming, check syringes and tubing
- During the priming, check transfer tip

Prior to each run:

- Check waste container and empty if necessary
- Check Wash Buffer Reservoir and add buffer if necessary
- Replace used D-cup racks
- Prime the system

Instrument Loading and System Operation

1. Examine the quantities of reagents on board the COBAS AMPLICOR Analyzer. Prepare enough reagent cassettes to complete the workload.

2. Mix NG PS1 well by vortexing. Add 2.5 mL NG PS1 to the NG4 cassette. Place the cassette on the test specific reagent rack. Discard the used NG PS1 vial. Record date of reagent preparation on the NG4 cassette.

3. Mix IC PS1 well by vortexing. Add 2.5 mL IC PS1 to the cassette containing IC4. Place the cassette on the test specific reagent rack. Discard the used IC PS1 vial. Record date of reagent preparation on the IC4 cassette.

4. Prepare the Working Substrate by pipetting 5 mL of SB into one SB3 cassette. Pipet up and down to mix. Discard the empty SB vial. Record the date of preparation on the SB3 cassette.

5. Place the Working Substrate in the generic reagent rack.

6. Place DN4 and CN4 cassettes on the generic reagent rack. Record the date each cassette was opened on cassette.

7. Identify the reagent racks as generic or test specific using the keypad or barcode scanner as described in the Operator’s Manual for the COBAS AMPLICOR Analyzer or by using the AMPLILINK® software as described in the Operator’s Manual for the AMPLILINK software.

8. Configure the reagent racks by inputting reagent positions and lot numbers into the instrument using the keypad or barcode scanner as described in the Operator’s Manual for the COBAS AMPLICOR Analyzer or by using the AMPLILINK software as described in the Operator’s Manual for the AMPLILINK software.

9. Load the reagent racks onto the instrument using the keypad or barcode scanner as described in the Operator’s Manual for the COBAS AMPLICOR Analyzer or by using the AMPLILINK software as described in the Operator’s Manual for the AMPLILINK software. Make sure that each reagent cassette is in its assigned position and that each cassette fits tightly into its rack.
10. Place the D-cup rack on the D-cup platform. One D-cup is required for each
detection of specimen or control and two D-cups are required for each cassette of Working Substrate to allow for blanking by the COBAS AMPLICOR Analyzer.

11. Place the A-ring(s) into the thermal cycler segment(s) of the COBAS AMPLICOR Analyzer.

12. Load the A-rings into the Analyzer using the keypad or barcode scanner as described in the Operator's Manual for the COBAS AMPLICOR Analyzer or by using the AMPLILINK software as described in the Operator's Manual for the AMPLILINK software.


14. Tightly close the cover of the thermal cycler segment(s).

15. Start the COBAS AMPLICOR Analyzer as described in the Operator's Manual for the COBAS AMPLICOR Analyzer.

16. Wait for Analyzer to indicate that the load check has passed.

**Note**

The COBAS AMPLICOR Analyzer permits up to 6 separate detections to be performed on the contents of each A-tube. The required quantity of each detection reagent is calculated by the Analyzer, and a load check performed at the start of each run determines if sufficient reagents are available for the requested test.

17. Amplification, dilution of amplicon, and detection are automatically performed by the COBAS AMPLICOR Analyzer. Qualitative results are expressed as positive or negative based on the absorbance value at 660 nm compared to a Test specific, predefined absorbance cut-off.

**Quality Control**

At least one replicate of the NG (+) Processed Control and one replicate of the NG (-) Processed Control must be included in each test run. As with any new laboratory procedure, new operators should consider the use of additional controls each time the test is performed until such time as a high degree of confidence is reached in their ability to perform the test correctly. Each laboratory may determine appropriate target values and limits using recommended methods, e.g., NCCLS C 24-A. There are no recommendations regarding the order of controls and specimens in the A-ring(s).

Additional controls may be tested according to guidelines or requirements of local, state, and/or federal regulations or accrediting organizations.

**Negative Control**

The absorbance of the NG (-) Control should be less than 0.2 at 660 nm. If the absorbance of the NG (-) Control is greater than or equal to 0.2, the entire run is invalid. Repeat the entire test process (specimen and control preparation, amplification, and detection). If the absorbance of the processed NG (-) Control is consistently greater than 0.2, contact your local Roche office for technical assistance. The NG (-) Control contains nonhomologous DNA (C. trachomatis sequences) and is intended to monitor contamination of reagents or equipment with target DNA.
Positive Control

The absorbance of the NG (+) Control should be greater than or equal to 2.0 at 660 nm. If the absorbance of the NG (+) Control is less than 2.0, the entire run is invalid. Repeat the entire test process (specimen and control preparation, amplification, and detection). If the absorbance of the NG (+) Control is consistently less than 2.0, contact your local Roche office for technical assistance.

The NG (+) Control contains approximately 20 copies/test of a *N. gonorrhoeae* plasmid DNA sequence. This is approximately four times the minimum detection level of the assay as determined by Poisson analysis. Amplification and detection of the NG (+) Control assures that amplification occurred. The NG (+) Control will not monitor amplification efficiency or the detection level of the Test.

Validation of Culture Transport Media and Specimen Collection Swabs

All new lots of Culture Transport Media (CTM) that are used to transport swab specimens to the laboratory for testing by the COBAS AMPLICOR CT/NG Test for *Neisseria gonorrhoeae* should be qualified for use with the Test to ensure that the media do not contain PCR interfering substances. Contact your local Roche office to obtain a copy of the Specimen Collection Swab and Transport Media Validation Procedure.

Specimen Processing Control

To test the effectiveness of sample processing, $10^4$ *N. gonorrhoeae* (available from the American Type Culture Collection) should be added to a tube of validated culture transport medium and incubated for 1 hour at room temperature. The spiked specimen should be processed and tested using the COBAS AMPLICOR CT/NG Swab Preparation Procedure as described in this Method Manual. Properly processed specimens should give positive COBAS AMPLICOR CT/NG Test results for *Neisseria gonorrhoeae* with an absorbance value greater than or equal to 3.5 at 660 nm.

Internal Control

The Internal Control is intended to identify specimens that contain polymerase inhibitors. The use of the Internal Control will not eliminate all false negative test results. In clinical studies, the proportion of inhibited specimens was highest for swab specimens from females (both symptomatic and asymptomatic) and urine specimens from symptomatic males. Use of the IC is recommended in order to obtain adequate performance with urine specimens from male patients. Use of the IC is an option for testing swab specimens from symptomatic and asymptomatic females and from symptomatic males, for testing only negative specimens, and for testing designated patients/specimen types in conformance with laboratory practices.
Results

Interpretation of Results  Without Internal Control Detection

Note  Refer to the Operator’s Manual for the COBAS AMPLICOR Analyzer for printing results and for the interpretation of flags and comments.

1. Check run printout for flags (FLG) and comments to ensure that the run is valid. If run is invalid, repeat the entire run (specimen and control preparation, amplification and detection).

2. For a valid run, specimen results are interpreted as follows:

<table>
<thead>
<tr>
<th>$A_{660}$</th>
<th>COBAS Flag</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 0.2</td>
<td>NEGATIVE</td>
<td><em>N. gonorrhoeae</em> DNA not detected. Specimen is presumptive negative for <em>N. gonorrhoeae</em>. A negative result does not preclude <em>N. gonorrhoeae</em> infection because results are dependent on adequate specimen collection, absence of inhibitors, and sufficient DNA to be detected.</td>
</tr>
<tr>
<td>$\geq 3.5$</td>
<td>POSITIVE</td>
<td><em>N. gonorrhoeae</em> DNA detected. <em>N. gonorrhoeae</em> organism viability and/or infectivity cannot be inferred since target DNA may persist in the absence of viable organisms.</td>
</tr>
<tr>
<td>$\geq 0.2$, $&lt; 3.5$</td>
<td>GZ 0.2 - 3.5</td>
<td>Equivocal. Results are inconclusive for <em>N. gonorrhoeae</em> DNA and additional patient testing is necessary. Process another aliquot of the original specimen and repeat the test in duplicate. Interpret results based on all three results (initial and duplicate repeats).* Alternatively, culture may be performed on the patient specimen.</td>
</tr>
</tbody>
</table>

* The final test interpretation of these specimens should be determined using 2.0 $A_{660}$ as the cutoff. A specimen yielding an initial equivocal result (GZ 0.2-3.5) must have duplicate repeat testing performed on another aliquot of the original specimen prior to reporting the final result. Specimens with at least 2 of 3 results (initial and duplicate repeats) with $A_{660}$ greater than or equal to 2.0 should be considered positive for *N. gonorrhoeae*. If 2 of 3 results have an $A_{660}$ less than 2.0, the specimen is presumptive negative for *N. gonorrhoeae*. 
Interpretation of Results  With Internal Control Detection

**Note**

Refer to the Operator's Manual for the COBAS AMPLICOR Analyzer for printing results and for the interpretation of flags and comments.

1. Check run printout for flags (FLG) and comments to ensure that the run is valid. If run is invalid, repeat the entire run (specimen and control preparation, amplification and detection).

2. For a valid run, specimen results are interpreted as follows:

<table>
<thead>
<tr>
<th>NG Specimen Result</th>
<th>IC Specimen Result</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>A&lt;sub&gt;660&lt;/sub&gt;</td>
<td>COBAS Flag</td>
<td>A&lt;sub&gt;660&lt;/sub&gt; COBAS Flag</td>
</tr>
<tr>
<td>&lt; 0.2</td>
<td>NEGATIVE</td>
<td>≥ 0.2 POSITIVE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>N. gonorrhoeae DNA not detected. Specimen is presumptive negative for N. gonorrhoeae. A negative result does not preclude Neisseria gonorrhoeae infection because results depend on adequate specimen collection, absence of inhibitors, and sufficient DNA to be detected.</td>
</tr>
</tbody>
</table>

| < 0.2              | NEGATIVE           | < 0.2 NEGATIVE |
|                    |                    | Inhibitory Specimen. N. gonorrhoeae DNA, if present, would not be detectable. Process another aliquot of the original specimen and repeat the test. Inhibitors are often labile and specimens initially inhibitory may not be inhibited when repeated. If the original specimen is not available, a new specimen must be collected. |

| ≥ 3.5              | POSITIVE           | ANY ANY        |
|                    |                    | N. gonorrhoeae DNA detected. N. gonorrhoeae organism viability and/or infectivity cannot be inferred since target DNA may persist in the absence of viable organisms. |

| ≥ 0.2, < 3.5       | GZ 0.2 - 3.5       | ANY ANY        |
|                    |                    | Equivocal      |
|                    |                    | Results are inconclusive for N. gonorrhoeae DNA and additional patient testing is necessary. Process another aliquot of the original specimen and repeat the test in duplicate. Interpret results based on all three test results (initial and duplicate repeats). Alternatively, culture may be performed on the patient specimen. |
3. For a valid run, specimens with a test result in the Grey Zone (≥ 0.2, < 3.5 at 660 nm) must have duplicate repeat testing performed on another aliquot of the original specimen, regardless of the IC result. The final test interpretation of these specimens should be determined using an absorbance value of 2.0 at 660 nm as the cutoff. Interpretation of repeat test results must be done according to the following tables:

**Step 1- Determine whether each repeat result is valid.**

<table>
<thead>
<tr>
<th>Repeat NG Test Result</th>
<th>Repeat IC Test Result</th>
<th>Interpretation of Assay Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>NG Result ≥ 0.2</td>
<td>Any IC Result</td>
<td>VALID</td>
</tr>
<tr>
<td>NG Result &lt; 0.2</td>
<td>IC Result ≥ 0.2</td>
<td>VALID</td>
</tr>
<tr>
<td>NG Result &lt; 0.2</td>
<td>IC Result &lt; 0.2</td>
<td>INVALID</td>
</tr>
</tbody>
</table>

**Step 2- Determine specimen result.**

<table>
<thead>
<tr>
<th>Initial NG Test Result and Repeat NG Test Results</th>
<th>Interpretation of Specimen Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 or more VALID test results ≥ 2.0</td>
<td><em>N. gonorrhoeae</em> DNA detected.</td>
</tr>
<tr>
<td>2 or more VALID test results &lt; 2.0</td>
<td><em>N. gonorrhoeae</em> DNA not detected.</td>
</tr>
<tr>
<td>a) One VALID result ≥ 2.0, one VALID result &lt; 2.0 and one INVALID test result</td>
<td>Results are inconclusive for <em>N. gonorrhoeae</em> DNA.</td>
</tr>
<tr>
<td><strong>OR</strong></td>
<td></td>
</tr>
<tr>
<td>b) 2 or more INVALID test results</td>
<td></td>
</tr>
</tbody>
</table>

**Determination of NG and Internal Control Cutoff.** The cutoffs for the NG specimen results and the IC specimen results were determined based on cumulative frequency distributions of absorbance values obtained with patient specimens (male urethral swabs from symptomatic males, female endocervical swabs, male urine) tested during preclinical studies and were confirmed in the clinical studies performed for the COBAS AMPLICOR CT/NG Test for *Neisseria gonorrhoeae*. These studies show that the majority of the time, a specimen with NG test results ≥ 3.5 A660 on the initial test will indicate the presence of *N. gonorrhoeae* as shown by culture. A specimen with NG test results < 0.2 A660 on the initial test correlates with negative *N. gonorrhoeae* culture results the majority of the time. Specimens with NG test results ≥ 0.2 A660 and < 3.5 A660 on the initial test are inconclusive for the presence of *N. gonorrhoeae* and require retesting. Upon repeat testing, specimens with two of the three cumulative test results ≥ 2.0 A660 a majority of the time indicate the presence of culturable *N. gonorrhoeae*. Specimens with two of the three cumulative test results < 2.0 A660 a majority of the time are negative for *N. gonorrhoeae* by culture. Similarly, the majority of the time, a specimen with IC test results > 0.2 A660 and having a NG test result < 0.2 A660 is negative for *N. gonorrhoeae* by culture.
Procedural Precautions

Workflow in the laboratory must proceed in a uni-directional manner, beginning in the Pre-Amplification Area and moving to the Post-Amplification (Amplification/Detection) Area. Pre-amplification activities must begin with reagent preparation and proceed to specimen preparation. Supplies and equipment must be dedicated to each Pre-amplification activity and not used for other activities or moved between areas. Gloves must be worn in each area and must be changed before leaving that area. Equipment and supplies used for reagent preparation must not be used for specimen preparation activities or for pipetting or processing amplified DNA or other sources of target DNA. Post-amplification supplies and equipment must remain in the Post-Amplification Area at all times.

As with any test procedure, good laboratory technique is essential to the proper performance of this assay. Due to the high analytical sensitivity of this test, extreme care should be taken to preserve the purity of kit reagents or amplification mixtures. All reagents should be closely monitored for purity. Discard any reagents that may be suspect.

The COBAS AMPLICOR CT/NG Test for Neisseria gonorrhoeae may detect non-pathogenic isolates of N. subflava and N. cinerea. These organisms may be a component of normal throat flora. Avoid contaminating specimen processing reagents, amplification reagents, and patient specimens with respiratory aerosols.

Procedural Limitations

Performance has only been established for the indicated specimen types (symptomatic male swabs, male urine, female endocervical swab specimens). Although evaluated with urine from females and swabs from asymptomatic males, the COBAS AMPLICOR CT/NG Test for Neisseria gonorrhoeae had reduced performance and is not recommended for testing female urine specimens or asymptomatic male swab specimens.

The interpretation of COBAS AMPLICOR CT/NG Test for Neisseria gonorrhoeae results for asymptomatic males requires caution due to the low prevalence of infection in this patient group and the short duration of asymptomatic infection\(^{19}\). Predictive values for a positive result will be lower in this group; the confidence of the sensitivity estimate for this group is reduced due to the low number of culture positive asymptomatic men sampled (1.7%, 12/719).

Prevalence of gonococcal infection in a population may affect performance. Positive predictive values decrease when testing populations with low prevalence or individuals with no risk of infection. See Table 2. Because the prevalence of N. gonorrhoeae may be low in some populations or patient groups, a false positive rate of 4% to 5% can exceed the true positive rate so that the predictive value of a positive test is very low (see Table 2). Since some patients that are truly infected will not be identified by testing a single specimen for culture, the true rate of false positives cannot be determined or presumed from the clinical data. The rate of false positive test results may depend on training, operator ability, reagent and specimen handling or other such factors in each laboratory. Culturing should be considered for confirmation and is required for antimicrobial susceptibility testing and retention for medico-legal purposes.
The COBAS AMPLICOR CT/NG Test for *Neisseria gonorrhoeae* is not recommended for evaluation of suspected sexual abuse and for other medico-legal indications.

Additional testing is recommended in any circumstance when false positive or false negative results could lead to adverse medical, social or psychological consequences.

Oropharyngeal aerosols or other sources of oropharyngeal contamination have a high probability of causing false-positive results for *N. gonorrhoeae*. The COBAS AMPLICOR CT/NG Test for *Neisseria gonorrhoeae* may detect non-pathogenic isolates of *N. subflava* and *N. cinerea*. These organisms may be a component of normal throat flora. Avoid contaminating specimen processing reagents, amplification reagents, and patient specimens with respiratory aerosols.

Detection of *N. gonorrhoeae* is dependent on the number of organisms present in the specimen and may be affected by specimen collection methods, patient factors (i.e., age, history of STD, presence of symptoms), stage of infection and/or infecting *Neisseria gonorrhoeae* strain.

False negative results may occur due to polymerase inhibition. The CT/NG IC has been added to the COBAS AMPLICOR CT/NG Test to permit the identification of processed specimens containing substances that may interfere with PCR amplification of greater than 20 copies/test.

The addition of AmpErase enzyme to the Master Mix enables selective amplification of target DNA; however, good laboratory practices and careful adherence to the procedures specified in this Method Manual are necessary to avoid contamination of reagents.

Therapeutic success or failure cannot be determined using this test.

As with any diagnostic test, results from the COBAS AMPLICOR CT/NG Test for *Neisseria gonorrhoeae* should be interpreted with consideration of all clinical and laboratory findings.

Use of this product should be limited only to personnel trained in the techniques of PCR.

Specimen storage recommendations are based on studies including 21 culture positive patient specimens (10 swabs and 11 urines) and 52 culture negative patient specimens.

The COBAS AMPLICOR CT/NG Test for *Neisseria gonorrhoeae* provides qualitative results. No correlation can be drawn between the magnitude of a positive COBAS Test absorbance signal and the number of *N. gonorrhoeae* cells within an infected specimen.

The COBAS AMPLICOR CT/NG Test for *Neisseria gonorrhoeae* for male urine testing is recommended to be performed on first catch random urine specimens (defined as the first 10 to 50 mL of the urine stream). The effects of other variables such as first-catch vs. mid-stream have not been evaluated.
The type and volume of Culture Transport Media used to transport swab specimens to the laboratory for testing by the COBAS AMPLICOR CT/NG Test for Neisseria gonorrhoeae may cause variable effects on the performance of the Test.

**Interfering Substances**

The presence of PCR inhibitors may cause false negative results.

Interfering substances include, but are not limited to the following:

- Replens® lubricant has been shown to inhibit PCR and may yield false negative results with this Test.

- The presence of mucus in cervical samples may inhibit PCR and cause false negative test results. Mucus free samples are recommended for optimal test performance. Use a sponge or a large swab to remove cervical secretions and discharge before obtaining the sample.

- Samples containing greater than 5% (v/v) blood may give false positive results. In Clinical studies, 681 of 2265 female swab specimens were noted to be bloody. False positive rates were not higher in these specimens.

**Expected Values**

**Prevalence**

The rate of positive N. gonorrhoeae test results in patient populations varies depending upon population characteristics such as age, sex, specimen type, risk factors and test methodology. The COBAS AMPLICOR CT/NG Test for N. gonorrhoeae clinical study was performed at 6 geographically diverse urban sites in the following states: Pennsylvania, Maryland, Louisiana, Indiana, Texas, California. The study included symptomatic and asymptomatic patients from the following populations: patients attending an STD Clinic, female patients at routine OB/GYN visits, female patients at prenatal care visits, patients attending adolescent health clinics, patients at family planning visits. The rate of positive COBAS AMPLICOR CT/NG Test for N. gonorrhoeae results in the clinical study ranged from 0% to 46.9%. The prevalence data from the study are shown by site in Table 1.
Table 1
COBAS AMPLICOR CT/NG Test for Neisseria gonorrhoeae
Prevalence Data

<table>
<thead>
<tr>
<th>Site</th>
<th>Sex</th>
<th>Symptoms</th>
<th>Specimen</th>
<th>N</th>
<th>No. Culture Positive</th>
<th>COBAS AMPLICOR Results (with IC)</th>
<th>% Positive</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No. Initially Inhibitory</td>
<td>No. Equivocal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Female</td>
<td>Symptomatic</td>
<td>Swab</td>
<td>277</td>
<td>33</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Male</td>
<td>Symptomatic</td>
<td>Swab</td>
<td>519</td>
<td>158</td>
<td>0</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Female</td>
<td>Symptomatic</td>
<td>Swab</td>
<td>120</td>
<td>7</td>
<td>6</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Male</td>
<td>Symptomatic</td>
<td>Swab</td>
<td>100</td>
<td>33</td>
<td>0</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Female</td>
<td>Symptomatic</td>
<td>Swab</td>
<td>240</td>
<td>5</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Male</td>
<td>Symptomatic</td>
<td>Swab</td>
<td>182</td>
<td>18</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Female</td>
<td>Symptomatic</td>
<td>Swab</td>
<td>244</td>
<td>3</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Male</td>
<td>Symptomatic</td>
<td>Swab</td>
<td>63</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Female</td>
<td>Symptomatic</td>
<td>Swab</td>
<td>32</td>
<td>13</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Male</td>
<td>Symptomatic</td>
<td>Swab</td>
<td>32</td>
<td>13</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Female</td>
<td>Symptomatic</td>
<td>Swab</td>
<td>211</td>
<td>26</td>
<td>6</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>Male</td>
<td>Symptomatic</td>
<td>Swab</td>
<td>48</td>
<td>137</td>
<td>2</td>
<td>33</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Predictive Values
The hypothetical positive and negative predictive values (PPV and NPV) for different prevalence rates using sensitivity and specificity of 97.1% and 98.1%, respectively, are shown in Table 2.

Table 2
COBAS AMPLICOR CT/NG Test for Neisseria gonorrhoeae
Hypothetical Predictive Values at Different Prevalence Rates

<table>
<thead>
<tr>
<th>Prevalence (%)</th>
<th>Sensitivity (%)</th>
<th>Specificity (%)</th>
<th>Positive Predictive Value (%)</th>
<th>Negative Predictive Value (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>97.1</td>
<td>98.1</td>
<td>34.5</td>
<td>99.9</td>
</tr>
<tr>
<td>5</td>
<td>97.1</td>
<td>98.1</td>
<td>73.3</td>
<td>99.8</td>
</tr>
<tr>
<td>10</td>
<td>97.1</td>
<td>98.1</td>
<td>85.3</td>
<td>99.7</td>
</tr>
<tr>
<td>20</td>
<td>97.1</td>
<td>98.1</td>
<td>92.9</td>
<td>99.3</td>
</tr>
</tbody>
</table>
The distribution of COBAS AMPLICOR CT/NG Test for *Neisseria gonorrhoeae* absorbance values from combined symptomatic and asymptomatic female swab specimens and symptomatic male swab specimens, and symptomatic and asymptomatic male urine specimens are shown in Figures 1 and 2, respectively. The $A_{660}$ values observed for 3480 swab specimens and 2008 urine specimens tested in the COBAS AMPLICOR CT/NG Test for *Neisseria gonorrhoeae* clinical study ranged from 0.000 to 4.000 for each specimen type. The histograms show a distinct separation of positive and negative test results. Figures 3 and 4 show the results for the swab specimen Internal Control and urine specimen Internal Control, respectively. The inhibitory specimens are those with values below 0.2 $A_{660}$.

**Figure 1**

**Swab Specimen Initial NG Absorbance Values**

**Combined Male and Female Data**
Figure 2
Urine Specimen Initial NG Absorbance Values
Male Data

Figure 3
Swab Specimen Initial IC Absorbance Values
Combined Male and Female Data
Performance Characteristics

Analytical Specificity

The analytical specificity of the COBAS AMPLICOR CT/NG Test for *Neisseria gonorrhoeae* was tested against 133 bacterial, 6 fungal, 1 protozoan and 11 viral strains that may be isolated from the urogenital tract. Each isolate was added to culture transport media and normal human urine using at least $10^4$ copies of genomic DNA per test (equivalent to $8 \times 10^5$ copies/mL in culture transport media and $4 \times 10^5$ copies/mL in urine specimens). The culture transport media and urine specimens were processed and tested using the standard COBAS AMPLICOR CT/NG Test procedure. Multiple isolates of *Neisseria subflava* and *Neisseria cinerea* obtained from the American Type Culture Collection and other sources were tested. Two of the *Neisseria subflava* isolates and one *Neisseria cinerea* isolate gave false positive test results.

The following organisms were tested and all gave negative results with the COBAS AMPLICOR CT/NG Test for *Neisseria gonorrhoeae*.

<table>
<thead>
<tr>
<th>Organism</th>
<th>Organism</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Achromobacter xerosis</em></td>
<td><em>Erysipelothrix rhusiopathiae</em></td>
</tr>
<tr>
<td><em>Acinetobacter calcoaceticus</em></td>
<td><em>Escherichia coli</em></td>
</tr>
<tr>
<td><em>Acinetobacter genosp. 3</em></td>
<td><em>Ewingella americana</em></td>
</tr>
<tr>
<td><em>Acinetobacter houfii</em></td>
<td><em>Flavobacterium meningosepticum</em></td>
</tr>
<tr>
<td><em>Actinomyces israelii</em></td>
<td><em>Gemella haemolyssans</em></td>
</tr>
<tr>
<td><em>Aerococcus viridans</em></td>
<td><em>Gemella morbillorum</em></td>
</tr>
<tr>
<td><em>Aeromonas hydrophila</em></td>
<td><em>Gardnerella vaginalis</em></td>
</tr>
<tr>
<td><em>Agrobacterium radiobacter</em></td>
<td><em>Haemophilus ducreyi</em></td>
</tr>
<tr>
<td><em>Alcaligenes faecalis</em></td>
<td><em>Haemophilus influenzae</em></td>
</tr>
<tr>
<td><em>Bacillus subtilis</em></td>
<td><em>Herpes simplex virus 1</em></td>
</tr>
<tr>
<td><em>Bacillus thuringiensis</em></td>
<td><em>Herpes simplex virus 2</em></td>
</tr>
<tr>
<td>Organism</td>
<td>Disease/Pathology</td>
</tr>
<tr>
<td>---------------------------------------------------</td>
<td>------------------------------------------------------</td>
</tr>
<tr>
<td>Neisseria gonorrhoeae</td>
<td>Human papilloma virus type 16</td>
</tr>
<tr>
<td>Neisseria cinerea</td>
<td>Neisseria subflava</td>
</tr>
<tr>
<td>Neisseria elongata</td>
<td>Neisseria gonorrhoeae</td>
</tr>
<tr>
<td>Neisseria sicca</td>
<td>Neisseria gonorrhoeae</td>
</tr>
<tr>
<td>Paracoccus denitrificans</td>
<td>Neisseria gonorrhoeae</td>
</tr>
<tr>
<td>Pasteurella maltocida</td>
<td>Neisseria gonorrhoeae</td>
</tr>
<tr>
<td>Pedicoccus acidilactica</td>
<td>Neisseria gonorrhoeae</td>
</tr>
<tr>
<td>Peptostreptococcus anaerobius</td>
<td>Neisseria gonorrhoeae</td>
</tr>
<tr>
<td>Peptostreptococcus magnus</td>
<td>Neisseria gonorrhoeae</td>
</tr>
<tr>
<td>Peptostreptococcus productus</td>
<td>Neisseria gonorrhoeae</td>
</tr>
<tr>
<td>Prevotella bivia</td>
<td>Neisseria gonorrhoeae</td>
</tr>
<tr>
<td>Prevotella corporis</td>
<td>Neisseria gonorrhoeae</td>
</tr>
<tr>
<td>Prevotella intermedia</td>
<td>Neisseria gonorrhoeae</td>
</tr>
<tr>
<td>Propionibacterium acnes</td>
<td>Neisseria gonorrhoeae</td>
</tr>
<tr>
<td>Proteus mirabilis</td>
<td>Neisseria gonorrhoeae</td>
</tr>
<tr>
<td>Providencia stuartii</td>
<td>Neisseria gonorrhoeae</td>
</tr>
<tr>
<td>Pseudomonas aeruginosa</td>
<td>Neisseria gonorrhoeae</td>
</tr>
<tr>
<td>Pseudomonas putida</td>
<td>Neisseria gonorrhoeae</td>
</tr>
<tr>
<td>Rahnella aquatilis</td>
<td>Neisseria gonorrhoeae</td>
</tr>
</tbody>
</table>

Some isolates from the following organisms may give false positive test results with the COBAS AMPLICOR CT/NG Test for Neisseria gonorrhoeae.
The analytical sensitivity of the COBAS AMPLICOR CT/NG Test for *Neisseria gonorrhoeae* was determined using fifteen stock cultures, each representing distinct gonococcal strains. Stock cultures of each strain were diluted in culture transport media and urine to prepare samples that contained 20, 10, 5, 2 and 1 CFU/test after specimen processing. For each isolate, three aliquots at each dilution were independently processed and tested using the standard test procedure.

The COBAS AMPLICOR CT/NG Test for *Neisseria gonorrhoeae* gave positive results for all strains tested at 20, 10, and 5 CFU/test. At 1 CFU/test, the Test gave positive results for at least one replicate of all 15 strains and positive results for all three replicates for 10 of the 15 strains tested. The analytical sensitivity (limit of detection) of the COBAS AMPLICOR CT/NG Test for *Neisseria gonorrhoeae* is 5 CFU/test (equivalent to 100 CFU/mL for urine specimens and 400 CFU/mL for CTM inoculated with a swab specimen) for culture transport media specimens and urine specimens.

A multi-operator study was performed to determine the qualitative precision of the COBAS AMPLICOR CT/NG Test for *Neisseria gonorrhoeae*. The study was based upon the design suggested in the NCCLS document EP5-A20. Three independent operators at three different geographical sites tested a panel of unprocessed urine and swab samples in duplicate, once a day, for three days. Each run consisted of specimen preparation, amplification and detection of the following samples in duplicate (number of specimens in parentheses): culture transport media samples containing 0 (4), 12.5 (2), 37.5 (2) and 62.5 (2) *Neisseria gonorrhoeae* CFU/test; and urine samples containing 0 (4), 10 (2), 30 (2) and 50 (2) *Neisseria gonorrhoeae* CFU/test. *Chlamydia trachomatis* was added to some culture transport media and urine specimens to determine test performance in the presence of a non-specific analyte. Tables 3 and 4 summarize the results from this study.

### Table 3

<table>
<thead>
<tr>
<th>N. gonorrhoeae Spiked CTM (CFU/test)</th>
<th>0</th>
<th>12.5</th>
<th>37.5</th>
<th>62.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Replicates</td>
<td>72</td>
<td>36</td>
<td>36</td>
<td>36</td>
</tr>
<tr>
<td>No. Correct Results (%)*</td>
<td>70 (100)</td>
<td>35 (100)</td>
<td>36 (100)</td>
<td>36 (100)</td>
</tr>
<tr>
<td>No. Equivocal A$_{660}$ 0.2-1.999</td>
<td>2†</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>No. Equivocal A$_{660}$ 2.0-3.499</td>
<td>0</td>
<td>11</td>
<td>10</td>
<td>8</td>
</tr>
<tr>
<td>Median A$_{660}$</td>
<td>0.002</td>
<td>3.932</td>
<td>3.984</td>
<td>3.968</td>
</tr>
<tr>
<td>Minimum A$_{660}$</td>
<td>0.000</td>
<td>1.554</td>
<td>2.925</td>
<td>3.266</td>
</tr>
<tr>
<td>Maximum A$_{660}$</td>
<td>0.023‡</td>
<td>4.000</td>
<td>4.000</td>
<td>4.000</td>
</tr>
</tbody>
</table>

* Specimens with initial equivocal results 0.2-1.999 were considered non-reportable, and were excluded from the calculations of % correct results. Specimens with equivocal results 2.0-3.499 were considered positive in the calculations.

† Both samples gave negative results when repeated in duplicate at the test site.

‡ Maximum absorbance excluding the two initial equivocal tests.
Table 4
COBAS AMPLICOR CT/NG Test for Neisseria gonorrhoeae
Urine Specimen Reproducibility

<table>
<thead>
<tr>
<th>N. gonorrhoeae Spiked Urine (CFU/test)</th>
<th>0</th>
<th>10</th>
<th>30</th>
<th>50</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Replicates</td>
<td>72</td>
<td>36</td>
<td>36</td>
<td>36</td>
</tr>
<tr>
<td>No. Correct Results (%)</td>
<td>72 (100)</td>
<td>26 (86.7)†</td>
<td>32 (100)</td>
<td>34 (100)</td>
</tr>
<tr>
<td>No. Equivocal A₆₆₀ 0.2-1.999</td>
<td>0</td>
<td>6</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>No. Equivocal A₆₆₀ 2.0-3.499</td>
<td>0</td>
<td>5</td>
<td>8</td>
<td>11</td>
</tr>
<tr>
<td>Median A₆₆₀</td>
<td>0.003</td>
<td>3.759</td>
<td>3.966</td>
<td>3.967</td>
</tr>
<tr>
<td>Minimum A₆₆₀</td>
<td>0.000</td>
<td>0.820§</td>
<td>0.771</td>
<td>1.518</td>
</tr>
<tr>
<td>Maximum A₆₆₀</td>
<td>0.024</td>
<td>4.000</td>
<td>4.000</td>
<td>4.000</td>
</tr>
</tbody>
</table>

* Specimens with initial equivocal results 0.2-1.999 were considered non-reportable, and were excluded from the calculations of % correct results. Specimens with equivocal results 2.0-3.499 were considered positive in the calculations.

† Two samples tested at one site gave a total of four negative test results. The specimens gave positive test results when repeated in duplicate at the site. % Correct calculation based on 26 correct results out of 30 tests.

§ The minimum absorbance excluding the four initial negative tests.

Control Performance
A summary of the performance of the positive and negative kit controls in the COBAS AMPLICOR CT/NG Test for Neisseria gonorrhoeae clinical study is shown in Table 5. The study was performed over a 9 month period by multiple operators at 6 clinical laboratories. During the course of the study, there were 19 invalid results due to the CTM controls (8 positive control, 11 negative control) and 10 invalid results due to the Urine controls (4 positive control, 6 negative control).

Table 5
COBAS AMPLICOR CT/NG Test for Neisseria gonorrhoeae
Control Results from Clinical Study

<table>
<thead>
<tr>
<th></th>
<th>CTM NG (+)</th>
<th>CTM NG (-)</th>
<th>Urine NG (+)</th>
<th>Urine NG (-)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Results</td>
<td>713</td>
<td>710</td>
<td>692</td>
<td>690</td>
</tr>
<tr>
<td>Median A₆₆₀</td>
<td>4.000</td>
<td>0.003</td>
<td>4.000</td>
<td>0.003</td>
</tr>
<tr>
<td>Mean A₆₆₀</td>
<td>3.930</td>
<td>0.006</td>
<td>3.930</td>
<td>0.005</td>
</tr>
<tr>
<td>Minimum A₆₆₀</td>
<td>2.011</td>
<td>0.000</td>
<td>2.055</td>
<td>0.000</td>
</tr>
<tr>
<td>Maximum A₆₆₀</td>
<td>4.000</td>
<td>0.194</td>
<td>4.000</td>
<td>0.173</td>
</tr>
</tbody>
</table>
Clinical Performance

The COBAS AMPLICOR CT/NG Test for *Neisseria gonorrhoeae* was evaluated in a clinical study conducted at six geographically diverse sites. Swab (endocervical for females, urethral for males) and urine specimens were obtained from all patients entered into the study. Swab specimens were placed in culture transport media (CTM) used at each site. All swab specimens were isolated by routinely used procedures (Modified Thayer Martin (MTM) plates, 4-10% CO₂) and identified with biochemical (acid production, substrate utilization) and serological (fluorescent antibody, coagglutination, monoclonal antibody-colloidal gold) methods. The performance of the COBAS AMPLICOR CT/NG Test for *Neisseria gonorrhoeae* was assessed with endocervical swab specimens obtained from female patients, urethral swabs from symptomatic male patients and urine specimens from symptomatic and asymptomatic male patients. Testing was repeated for all specimens with initial values in the range of 0.0 to 0.199 A₆₆₀ when IC results were inhibited (negative), and for all specimens with initial values in the range of 0.2 to 3.5 A₆₆₀.

The clinical performance of the COBAS AMPLICOR CT/NG Test for *Neisseria gonorrhoeae* was evaluated by comparing the results of the 5486 swab and urine specimens to the *Neisseria gonorrhoeae* culture results. Specimens with discrepant results were also tested by an alternate primer (16S rRNA) PCR test. Analyses were also performed including and excluding the use of the Internal Control result. The alternate primer PCR test results were not used to calculate the clinical performance characteristics of the test and are reported for information purposes only.

When the Internal Control result was used in the analysis, specimens with repeatedly negative Internal Control test results were excluded because the results were not interpretable. Of the 5486 specimens collected and tested in the COBAS AMPLICOR CT/NG Test clinical study, 44 were repeatedly inhibitory. Therefore, a total of 5442 specimens were used in the analyses when the Internal Control result was used. Table 6 shows the results from the clinical study. Table 7 provides a detailed summary of the performance of the Internal Control, and includes initial and repeat inhibitory results by culture, patient sex, and specimen type.

The clinical sensitivity and specificity of the COBAS AMPLICOR CT/NG Test for *Neisseria gonorrhoeae* has not been reliably determined for detecting those patients with clinically active infection that can be transmitted to partners or cause gonorrhea-related sequelae. In the clinical study described here, 9.7% of all positive results (18.6% for females) were from patients with negative cultures. The significance of those results that were positive, but culture negative is unknown. A proportion of these positive specimens (61.6%) were also positive by an alternate target PCR assay; however, the performance of this alternate target assay has not been established.
### Table 6
Clinical Performance Of COBAS AMPLICOR CT/NG Test for Neisseria gonorrhoeae Including and Excluding the Internal Control

<table>
<thead>
<tr>
<th>Sex</th>
<th>Specimen</th>
<th>Symptom</th>
<th>TP</th>
<th>TN</th>
<th>FP</th>
<th>FN</th>
<th>No. Inhib</th>
<th>% Repeatedly Inhibitory</th>
<th>Total</th>
<th>Sensitivity (95% CI)</th>
<th>Specificity (95% CI)</th>
<th>16Sv/FP*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td>Asymptomatic</td>
<td>CTM</td>
<td>49</td>
<td>1026</td>
<td>13</td>
<td>1</td>
<td>12</td>
<td>1.15%</td>
<td>1101</td>
<td>98.0% (93.9-99.9)</td>
<td>98.7% (98.1-99.4)</td>
<td>5/13</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(49)</td>
<td>(1039)</td>
<td>(12)</td>
<td>(1)</td>
<td></td>
<td></td>
<td>(1101)</td>
<td></td>
<td>(98.9%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symptomatic</td>
<td></td>
<td>69</td>
<td>1032</td>
<td>14</td>
<td>4</td>
<td>18</td>
<td>1.71%</td>
<td>1137</td>
<td>94.5% (86.6-98.5)</td>
<td>98.7% (90.0-99.4)</td>
<td>9/14</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(69)</td>
<td>(1050)</td>
<td>(13)</td>
<td>(5)</td>
<td></td>
<td></td>
<td>(1137)</td>
<td></td>
<td>(98.8%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total for Females</td>
<td></td>
<td>118</td>
<td>2058</td>
<td>27</td>
<td>5</td>
<td>30</td>
<td>1.43%</td>
<td>2238</td>
<td>95.9% (90.8-98.7)</td>
<td>98.7% (98.2-99.2)</td>
<td>14/27</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(118)</td>
<td>(2089)</td>
<td>(25)</td>
<td>(6)</td>
<td></td>
<td></td>
<td>(2238)</td>
<td></td>
<td>(98.8%)</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>Asymptomatic</td>
<td>URINE</td>
<td>9</td>
<td>703</td>
<td>3</td>
<td>3</td>
<td>1</td>
<td>0.14%</td>
<td>719</td>
<td>75.0% (62.8-84.5)</td>
<td>99.6% (98.8-99.9)</td>
<td>2/3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(8)</td>
<td>(704)</td>
<td>(3)</td>
<td>(4)</td>
<td></td>
<td></td>
<td>(719)</td>
<td></td>
<td>(96.7%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symptomatic</td>
<td></td>
<td>336</td>
<td>904</td>
<td>22</td>
<td>14</td>
<td>11</td>
<td>1.18%</td>
<td>1287</td>
<td>96.0% (85.9-98.1)</td>
<td>97.6% (96.6-98.6)</td>
<td>18/22</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(310)</td>
<td>(907)</td>
<td>(21)</td>
<td>(49)</td>
<td></td>
<td></td>
<td>(1287)</td>
<td></td>
<td>(97.7%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total for Males</td>
<td></td>
<td>687</td>
<td>2469</td>
<td>59</td>
<td>19</td>
<td>14</td>
<td>0.56%</td>
<td>3248</td>
<td>97.3% (91.6-98.5)</td>
<td>97.7% (97.1-98.3)</td>
<td>39/59</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(660)</td>
<td>(2476)</td>
<td>(57)</td>
<td>(55)</td>
<td></td>
<td></td>
<td>(3248)</td>
<td></td>
<td>(97.7%)</td>
<td></td>
</tr>
</tbody>
</table>

1 Numbers in parenthesis show the performance results when the Internal Control was not used.

* Number of apparent false positive COBAS AMPLICOR Test results that were positive by alternate primer pair PCR/Total number of apparent COBAS AMPLICOR false positive results.
<table>
<thead>
<tr>
<th>Culture Results</th>
<th>Specimen Group</th>
<th>Specimen</th>
<th>COBAS AMPLICOR Results</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sex</td>
<td></td>
<td>Initial Inhibitory (%)</td>
</tr>
<tr>
<td>Negative</td>
<td>Female</td>
<td>Asymptomatic</td>
<td>CTM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Symptomatic</td>
<td>CTM</td>
</tr>
<tr>
<td></td>
<td>Male</td>
<td>Symptomatic</td>
<td>CTM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Asymptomatic</td>
<td>Urine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Symptomatic</td>
<td>Urine</td>
</tr>
<tr>
<td>Total Males and Females, Culture Negative</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>Female</td>
<td>Asymptomatic</td>
<td>CTM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Symptomatic</td>
<td>CTM</td>
</tr>
<tr>
<td></td>
<td>Male</td>
<td>Asymptomatic</td>
<td>Urine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Symptomatic</td>
<td>Urine</td>
</tr>
<tr>
<td>Total Males and Females, Culture Positive</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total All Results</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
References


5. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance, 2002. Division of STD/HIV Prevention, Centers for Disease Control and Prevention, Atlanta, GA.


Neisseria gonorrhoeae